Florida Cancer Specialists & Research Institute, LLC

https://flcancer.com/

Florida Cancer Specialists & Research Institute (FCS) is a leading provider of community-based oncology and hematology services, dedicated to delivering world-class cancer care close to home. Headquartered in Fort Myers, Florida, the organization focuses on compassionate patient care, innovative clinical research, and the application of cutting-edge technologies and treatments.

FCS offers a comprehensive range of services including medical oncology, hematology, radiation oncology, pathology, and diagnostic imaging. A key differentiator is its robust clinical research program, providing patients access to more clinical trials than any other private oncology practice in Florida, often leading the nation in initiating studies for groundbreaking therapies. The institute also provides genomic-based treatments, immunotherapy, and a specialty pharmacy service (Rx To Go), alongside various patient support services.

As the largest independent medical oncology/hematology practice in the United States, FCS operates nearly 100 locations across Florida. In a significant development, McKesson Corporation acquired a 70% controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures), an administrative services organization established by FCS, in 2025. While FCS physicians retained a 30% interest in Core Ventures and FCS itself remains independently owned, it has joined McKesson's The US Oncology Network. The leadership team includes President & Managing Physician Dr. Lucio N. Gordan and CEO Ryan Ciarrocchi.

Latest updates

Florida Cancer Specialists Highlights Innovation in Community Oncology

Event summary

  • Florida Cancer Specialists (FCS) leaders presented at the Community Oncology Alliance (COA) 2026 conference, focusing on solutions for community oncology providers.
  • Presentations included discussions on CAR-T therapy access, advocacy strategies, pharmacist optimization, and the use of AI tools in oncology.
  • FCS conducts over 180 active clinical trials annually, positioning them as a research leader among private oncology practices.
  • FCS has provided patients access to cancer drugs approved by the FDA through clinical trial participation prior to approval.

The big picture

FCS's emphasis on innovation and clinical trials underscores the ongoing challenges facing community oncology providers, who are navigating rising costs, evolving treatment options, and increasing regulatory scrutiny. The company's focus on technology and advocacy suggests a proactive approach to adapting to these pressures and maintaining its position within a consolidating market. The reliance on partnerships like Sarah Cannon Research Institute highlights the need for collaboration to drive innovation and access in a fragmented healthcare landscape.

What we're watching

Technology Adoption
The integration of agentic AI and other tech tools into community oncology workflows will determine whether these solutions translate to improved patient outcomes and operational efficiency beyond demonstration projects.
Regulatory Landscape
Changes in reimbursement models and regulatory approvals for CAR-T therapies and other advanced treatments will significantly impact FCS’s ability to expand access and maintain profitability.
Clinical Trial Growth
The pace at which FCS can expand its clinical trial participation, particularly in late-phase research, will be a key indicator of its ability to attract innovative therapies and maintain a competitive edge.

Florida Cancer Specialists Summit Signals Shift to AI-Driven Oncology

Event summary

  • Florida Cancer Specialists & Research Institute (FCS) hosted its Fifth Annual National General Medical Oncology Summit in Orlando on April 24, 2026.
  • The summit featured presentations and discussions focused on emerging treatment strategies and data, with a focus on personalized cancer care.
  • Keynote speaker Doug Flora, MD, emphasized the integration of AI in cancer care and discussed his book, 'Rebooting Cancer Care'.
  • FCS conducts over 180 active clinical trials annually, positioning it as a leader in research among private oncology practices.
  • FCS physicians and hematologists presented on a range of oncology topics, including chronic lymphocytic leukemia, colorectal cancer, and targeted therapies.

The big picture

The summit highlights a broader trend in oncology towards personalized medicine and the increasing adoption of AI to improve diagnostics and treatment. FCS’s focus on community settings positions it to serve a large patient base, but its success hinges on its ability to integrate these advanced technologies and demonstrate value-based care outcomes. The emphasis on clinical trials underscores the importance of innovation in maintaining a competitive edge within a rapidly evolving pharmaceutical landscape.

What we're watching

AI Integration
The extent to which FCS can operationalize AI-driven insights from Doug Flora’s presentation will be a key indicator of its competitive advantage in oncology care. Successful implementation could accelerate treatment efficacy and improve patient outcomes, but requires significant investment and workforce training.
Clinical Trial Pipeline
The continued success of FCS’s clinical trial program, particularly its partnership with SCRI, will be crucial for maintaining access to innovative therapies and attracting patients. A slowdown in trial approvals or enrollment could impact revenue and market share.
Value-Based Care
Maen Hussein’s role as medical director of value-based care suggests a strategic shift towards outcome-based reimbursement models. The ability to demonstrate improved patient outcomes and reduced costs will be essential for securing favorable contracts with payers.

Florida Cancer Specialists Showcases Pharmacy Integration, Clinical Trial Access

Event summary

  • Florida Cancer Specialists & Research Institute (FCS) presented at the NCODA International Spring Forum in Denver on April 15, 2026.
  • FCS leaders presented on specialty pharmacy operations, patient navigation, and real-world evidence analysis related to cancer treatment.
  • FCS’s in-house specialty pharmacy, ‘Rx To Go,’ exclusively serves patients within the statewide practice.
  • FCS has provided patients access to clinical trials, often before FDA approval, positioning them as a leader in oncology research.

The big picture

FCS’s emphasis on integrated pharmacy services and clinical trial access highlights a strategic shift towards value-based care and personalized medicine within the community oncology landscape. The practice’s model, while successful, faces increasing pressure from larger healthcare providers and the rising cost of specialty pharmaceuticals. Their focus on real-world data suggests an attempt to demonstrate clinical and economic value, a critical factor for reimbursement and market positioning.

What we're watching

Pharmacy Integration
The success of FCS’s integrated pharmacy model ('Rx To Go') will be a key indicator of whether community oncology practices can effectively compete with larger, vertically integrated healthcare systems.
Clinical Trial Access
The continued ability of FCS to offer clinical trials before FDA approval will depend on maintaining strong relationships with pharmaceutical companies and navigating evolving regulatory pathways.
Real-World Data
The utility of FCS’s real-world evidence analysis, particularly concerning Zanubrutinib, will determine its ability to influence treatment protocols and potentially attract further research funding.

Immunotherapy Approval Boosts Florida Cancer Specialists' Research Profile

Event summary

  • The FDA approved KEYTRUDA and KEYTRUDA QLEX for treating recurrent ovarian cancer in adults with PD-L1 expression and platinum-resistant disease.
  • Florida Cancer Specialists & Research Institute (FCS) contributed to the late-phase clinical research supporting the approval.
  • Dr. Bradley Monk, FCS's medical director of late-phase clinical research, presented the findings at the SGO annual meeting and published them in The Lancet.
  • The treatments target a significant patient population: approximately 75% of ovarian cancer cases express PD-L1.
  • FCS conducts over 180 active clinical trials annually, leveraging a partnership with Sarah Cannon Research Institute.

The big picture

The FDA approval represents a significant advancement in treating platinum-resistant ovarian cancer, a disease with historically poor outcomes. FCS's participation underscores the growing importance of community-based cancer centers in driving oncology research and providing patients with access to cutting-edge therapies. This approval also highlights the increasing role of immunotherapy in treating cancers previously reliant on chemotherapy.

What we're watching

Market Adoption
The speed of adoption of these new therapies will depend on physician familiarity and patient access, potentially impacting peak sales for Merck (KEYTRUDA's manufacturer).
Trial Pipeline
FCS's continued involvement in clinical trials, as evidenced by Dr. Monk's presentation on endometrial cancer, suggests a broader strategy to expand its research portfolio and access to novel therapies.
Competitive Landscape
The emergence of immunotherapy options will likely intensify competition within the ovarian cancer treatment market, potentially impacting pricing and market share for existing therapies.

Florida Cancer Specialists Amplifies Industry Influence at FLASCO Summit

Event summary

  • Florida Cancer Specialists (FCS) is participating in the FLASCO 2026 Spring Congress and Business of Oncology Summit in Orlando, April 10-11.
  • Richard McDonough, MD, FCS’s director of advocacy & policy, will be a panelist discussing workforce transformation in oncology.
  • FCS conducts over 180 active clinical trials annually, positioning it as a research leader.
  • Dr. McDonough, a past president and current board member of FLASCO, is hosting a reception for fellows and residents.

The big picture

Florida Cancer Specialists’ active participation in FLASCO underscores the increasing importance of industry collaboration and advocacy in navigating the evolving oncology landscape. The company’s focus on clinical research and workforce development reflects broader trends toward precision medicine and addressing the growing demand for cancer care services, particularly as the population ages. FCS’s position as a leader in clinical trials provides a competitive advantage, but also increases its exposure to regulatory changes and payer pressures.

What we're watching

Workforce Dynamics
The discussion around workforce transformation at FLASCO will likely highlight the ongoing shortage of oncology professionals and the need for innovative training and retention strategies, potentially impacting care delivery models and costs.
Research Funding
FCS’s reliance on partnerships like Sarah Cannon Research Institute suggests a continued need for external funding to sustain its robust clinical trial program, making grant acquisition and collaborative agreements critical to its future growth.
Policy Influence
Dr. McDonough’s role in FLASCO and his advocacy focus indicate that FCS will actively shape policy discussions impacting oncology care in Florida, potentially influencing reimbursement rates and regulatory frameworks.

Gotistobart Trial Data Suggests Potential Advance in NSCLC Immunotherapy

Event summary

  • Florida Cancer Specialists & Research Institute (FCS) participated in Stage 1 of the PRESERVE-003 Phase 3 clinical trial evaluating gotistobart, a novel CTLA-4 checkpoint inhibitor.
  • The trial, involving centers in the U.S., Australia, China, Korea, and the UK, ran from June 2023 to September 2024.
  • Initial findings, published in Nature Medicine, suggest gotistobart may offer improved effectiveness and fewer side effects compared to docetaxel in patients with metastatic squamous NSCLC.
  • The trial's primary endpoint is overall survival (OS), with secondary endpoints including progression-free survival (PFS), objective response rate (ORR), and safety.

The big picture

The PRESERVE-003 trial highlights the ongoing effort to improve outcomes for patients with advanced NSCLC, a disease with historically limited treatment options. The focus on CTLA-4 checkpoint inhibition represents a refinement of immunotherapy approaches, aiming to enhance efficacy while mitigating adverse effects. FCS's participation underscores the growing importance of community-based clinical research in accelerating drug development and expanding patient access to innovative therapies.

What we're watching

Clinical Validation
The success of Stage 1 results will be critically dependent on replication in the larger, pivotal Stage 2 of the PRESERVE-003 trial, which will determine if the observed benefits are statistically significant and clinically meaningful.
Regulatory Pathway
The FDA’s assessment of gotistobart’s safety and efficacy profile, particularly concerning the observed reduction in side effects, will be a key factor in its potential market approval and adoption.
Competitive Landscape
The emergence of gotistobart will likely intensify competition within the NSCLC immunotherapy market, potentially impacting the sales and market share of existing treatments like docetaxel and other checkpoint inhibitors.

KRAS-Targeted Therapy Shows Promise in Phase 1 Trial, FCS Contributes

Event summary

  • Florida Cancer Specialists & Research Institute (FCS) participated in a Phase 1 clinical study evaluating setidegrasib, a first-in-class KRAS G12D inhibitor.
  • The study, published in the New England Journal of Medicine, demonstrated antitumor activity in patients with advanced non-small-cell lung cancer and pancreatic cancer harboring KRAS G12D mutations.
  • KRAS G12D mutations occur in 5% of NSCLC patients and 40% of pancreatic ductal adenocarcinoma patients, representing a significant unmet need.
  • Study results have informed dosing for the upcoming Phase 2 clinical trial.

The big picture

The successful Phase 1 results represent a significant breakthrough in targeting the KRAS G12D mutation, a long-standing challenge in oncology. FCS’s participation underscores its growing role as a key player in early-phase clinical trials and its positioning to benefit from the development of innovative cancer therapies. The publication in the New England Journal of Medicine lends significant credibility to the therapy and the research program at FCS.

What we're watching

Clinical Progression
The success of Phase 2 trials will be critical in determining setidegrasib’s viability as a commercial therapy, and FCS’s involvement will be a key indicator of its potential.
Market Adoption
Given the relatively high prevalence of KRAS G12D mutations in pancreatic cancer, market adoption will depend on demonstrating a clear clinical benefit over existing treatments and managing potential adverse effects.
Competitive Landscape
Other companies are pursuing KRAS-targeted therapies; the pace of their development and clinical results will influence setidegrasib’s market share and pricing power.

Florida Cancer Specialists Bolsters GI Oncology Expertise with Yao Hire

Event summary

  • Florida Cancer Specialists (FCS) has hired Xin Yao, MD, a board-certified medical oncologist and hematologist, effective immediately.
  • Dr. Yao will practice at FCS clinics in Naples and Estero, Lee County, Florida.
  • He previously worked as a medical oncologist at Cleveland Clinic in Stuart, Florida.
  • Dr. Yao serves as community chair for GI oncology with the ECOG-ACRIN Cancer Research Group.

The big picture

Florida Cancer Specialists’ strategic hiring of Dr. Yao underscores the ongoing consolidation and specialization within the oncology services market. The emphasis on gastrointestinal oncology reflects the increasing prevalence of GI cancers and the demand for specialized care. FCS’s commitment to clinical research and its affiliation with ECOG-ACRIN positions it to capitalize on emerging therapies and maintain a competitive edge in a rapidly evolving field.

What we're watching

Clinical Focus
Dr. Yao’s specialization in gastrointestinal oncology suggests FCS is strategically expanding its capabilities in a high-prevalence cancer area, which could impact patient volume and referral patterns.
Research Alignment
The ECOG-ACRIN affiliation indicates a continued emphasis on clinical research and access to trials, which may influence drug pricing and reimbursement negotiations.
Competitive Landscape
FCS’s acquisition of talent from Cleveland Clinic signals an ongoing battle for market share within Florida’s oncology landscape, potentially impacting pricing and service offerings.

Florida Cancer Specialists Presents Early Data on Novel Prostate, Urothelial Cancer Therapies

Event summary

  • Florida Cancer Specialists (FCS) physicians presented initial findings from two clinical trials at the ASCO 2026 Genitourinary Cancers Symposium.
  • One trial (Phase 1b) assessed the combination of pasritamig (PAS) and docetaxel (DOCE) for metastatic castration-resistant prostate cancer (mcrPC).
  • The other trial (Phase 1/2) evaluated AVZO-103, a bispecific Nectin4/Trop2 antibody-drug conjugate (ADC), for urothelial cancer and other solid tumors.
  • Manish Patel, MD, led the prostate cancer study, while Cesar Augusto Perez, MD, co-authored the urothelial cancer study.
  • The findings underscore FCS’s commitment to clinical research and accelerating new treatment options.

The big picture

The presentation highlights the ongoing shift towards precision medicine and targeted therapies in genitourinary cancers, a market segment representing a significant portion of the overall cancer burden in the US. FCS’s focus on clinical trials positions it to capitalize on this trend, but also exposes it to the inherent risks associated with early-stage drug development and dependence on external research organizations. The data presented, while preliminary, could influence investment decisions and partnerships within the oncology space.

What we're watching

Clinical Efficacy
The initial Phase 1b results for pasritamig and docetaxel will be scrutinized for signs of meaningful clinical benefit in mcrPC, as this combination represents a potential new approach to a difficult-to-treat cancer.
ADC Adoption
The progress of AVZO-103, a bispecific ADC, will be watched closely, as the success of this therapy could validate the broader ADC approach in urothelial cancer and other solid tumors.
Partner Reliance
FCS’s continued reliance on partnerships like Sarah Cannon Research Institute will determine the breadth and depth of its clinical trial pipeline and ability to compete in the oncology research landscape.

Florida Cancer Specialists Expands Bayfront Presence with Orlando Health Collaboration

Event summary

  • Florida Cancer Specialists & Research Institute (FCS) opened a 31,000 square-foot facility in St. Petersburg, Florida, on February 13, 2026.
  • The new location is part of the Orlando Health Institute Square development.
  • The facility employs six medical oncologists and hematologists, supported by four advanced practice practitioners.
  • The clinic offers services including on-site PET/CT imaging, infusion chairs, and access to clinical trials and advanced therapies like bispecific treatments and cell therapy.

The big picture

This expansion reflects a broader trend of healthcare providers seeking to integrate specialized services with hospital systems to enhance patient access and care coordination. The investment in advanced therapies signals a commitment to staying at the forefront of oncology treatment, positioning FCS to compete for patients seeking cutting-edge care. The partnership with Orlando Health suggests a strategic move to leverage the hospital’s infrastructure and referral network to expand FCS’s reach within the Tampa Bay area.

What we're watching

Market Penetration
The success of this expansion hinges on FCS’s ability to capture market share in Pinellas County, given its existing presence of six other sites in the region; cannibalization of existing patient volume will be a key indicator.
Integration Risk
The collaborative model with Orlando Health requires seamless integration of workflows and data systems, and any friction could negatively impact patient outcomes and operational efficiency.
Therapy Adoption
The clinic’s investment in advanced therapies like cell therapy will require ongoing training and infrastructure upgrades, and the rate of patient adoption will determine the return on investment.

Florida Cancer Specialists Bolsters Lake County Presence with Key Oncologist Hire

Event summary

  • Florida Cancer Specialists (FCS) has added Aamir Hussain, MD, a board-certified medical oncologist and hematologist, to its team.
  • Dr. Hussain will practice at FCS clinics in Clermont and Tavares, Florida, focusing on prostate, breast, and lymphoma cancers.
  • Dr. Hussain brings over 12 years of experience across various oncology settings and a history of peer-reviewed publications and clinical symposium presentations.
  • He holds prior leadership positions as chief resident and chief fellow at SUNY Buffalo and NIH respectively.

The big picture

This expansion signals FCS's continued focus on geographic reach and specialized oncology care within Florida. The addition of a physician with a strong research background reinforces the company’s strategy of leveraging clinical trials to offer cutting-edge treatments and attract patients. FCS's position as a leader in clinical trials within Florida's oncology market, and potentially nationally, provides a significant competitive advantage, but also increases scrutiny regarding trial efficacy and patient safety.

What we're watching

Patient Acquisition
The impact of Dr. Hussain's specialization in prostate, breast, and lymphoma cancers on patient volume and revenue generation within the Lake County clinics warrants monitoring.
Research Integration
FCS's ability to leverage Dr. Hussain's research background to expand clinical trial participation and potentially accelerate drug approvals will be a key indicator of its competitive advantage.
Competitive Landscape
The response of competing oncology practices in the Lake County area to FCS's expansion and the addition of a physician with Dr. Hussain’s credentials should be observed.

Florida Cancer Specialists Advances GI Cancer Research with Multiple Clinical Trial Presentations

Event summary

  • Florida Cancer Specialists & Research Institute (FCS) presented research at the ASCO Gastrointestinal Cancers Symposium in January 2026.
  • Dr. Ivor Percent presented results from a Phase 2 study (1801 Part 3B) evaluating elraglusib plus gemcitabine/nab-paclitaxel (GnP) in pancreatic ductal adenocarcinoma.
  • FCS physicians co-authored three additional studies focusing on novel treatments for colorectal and pancreatic cancers, including tovecimig (CTX-009) and ASP3082.
  • ASP3082 is a first-in-class selective protein degrader being evaluated for KRAS G12D-mutant pancreatic ductal adenocarcinoma.

The big picture

FCS’s continued emphasis on clinical research and early-phase trials underscores a strategy to remain at the forefront of cancer treatment innovation. This approach allows them to offer patients access to cutting-edge therapies before they are widely available, potentially attracting patients and referrals. The focus on gastrointestinal cancers, a significant area of unmet need, highlights a targeted approach to research and development within the broader oncology market.

What we're watching

Clinical Efficacy
The results of the elraglusib study will be scrutinized to determine if the combination therapy demonstrates a statistically significant improvement in patient outcomes for mPDAC, potentially impacting treatment protocols.
Pipeline Progress
The advancement of ASP3082, a novel protein degrader, will be closely monitored as it moves through clinical trials, given the high unmet need for therapies targeting KRAS mutations.
Competitive Landscape
How FCS’s early access to and participation in clinical trials for novel therapies positions them relative to other oncology practices and influences patient recruitment and referral patterns remains to be seen.

Florida Cancer Specialists Bolsters Pasco County Presence with Experienced Oncologist

Event summary

  • Florida Cancer Specialists (FCS) has hired Dr. H. Bindu Lingam, a medical oncologist and hematologist with 20 years of experience.
  • Dr. Lingam will practice at the FCS Hudson clinic and Trinity Cancer Center in Pasco County, Florida.
  • Dr. Lingam previously held roles at the FDA, NIH, and Veterans Affairs Health Administration.
  • She holds an AI in Healthcare certification from MIT.

The big picture

The addition of Dr. Lingam underscores Florida Cancer Specialists’ continued investment in expanding its geographic reach and bolstering its clinical expertise. The focus on both clinical trials and compassionate care reflects a broader trend in oncology towards personalized medicine and patient-centric approaches. FCS’s position as a leader in clinical trials provides a competitive advantage, but its ability to translate that into sustained patient growth and profitability will be crucial.

What we're watching

Clinical Integration
Dr. Lingam’s experience with federal agencies suggests a focus on data-driven and equitable care delivery; the extent to which this translates into operational changes at FCS will be key to observe.
Market Penetration
FCS’s expansion into Pasco County, coupled with the addition of a specialist with Dr. Lingam’s profile, indicates an aggressive strategy to capture market share in a competitive oncology landscape.
AI Adoption
Dr. Lingam’s AI in Healthcare certification signals a potential shift towards incorporating AI tools into FCS’s treatment protocols, though the timeline and impact remain to be seen.

Florida Cancer Specialists Bolsters Ocala Presence with New Oncologist

Event summary

  • Florida Cancer Specialists (FCS) has added Sarath Katragadda, MD, MSc, to its team in Marion County, Florida.
  • Dr. Katragadda specializes in genitourinary, gastrointestinal, and breast cancers and will practice at two Ocala locations.
  • He previously served as assistant clinical professor at the University of South Florida’s oncological sciences department.
  • FCS has operated for over 40 years and emphasizes clinical research, often providing early access to new cancer drugs.

The big picture

Florida Cancer Specialists’ continued expansion, particularly through physician recruitment, reflects the ongoing consolidation and specialization within the oncology services market. The company’s focus on clinical trials positions it as a key player in the development and early adoption of new cancer therapies, a strategy that can drive both revenue and patient acquisition. This expansion also highlights the increasing demand for specialized cancer care in Florida’s growing population.

What we're watching

Market Penetration
The addition of Dr. Katragadda suggests FCS is actively seeking to expand its market share within Marion County, potentially indicating increased competition among oncology providers in the region.
Clinical Focus
FCS’s specialization in genitourinary, gastrointestinal, and breast cancers will likely influence the types of clinical trials offered and the patient demographics served at the Ocala locations.
Academic Ties
Dr. Katragadda’s role as an assistant clinical professor at USF could facilitate research collaborations and potentially attract further talent to FCS, impacting its clinical trial pipeline.
CID: 385